SEATTLE, Oct. 29, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq: NSTG ), announced today that its management is scheduled to present at the Credit Suisse 2013 Healthcare Conference in Phoenix on Tuesday, November 12, 2013 at 8:30 am MT/ 10:30 am ET.
Interested parties can access the live audio webcast for the conference at www.nanostring.com . The webcast replay of the presentation will begin after the conclusion of the live presentation and will be available for approximately 30 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business.
For more information, please visit www.nanostring.com .
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
Investor Contact: Lynn Pieper of Westwicke Partners For NanoString Technologies 415-202-5678 Media Contact: Nicole Litchfield For NanoString Technologies 415-793-6468
